GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2020-09-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 144
- Registration Number
- NCT02864381
Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant
- Conditions
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 51
- Registration Number
- NCT02862548
- Locations
- 🇳🇿
Auckland City Hospital, Auckland, New Zealand
Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 15
- Registration Number
- NCT02862574
- Locations
- 🇺🇸
Albuquerque Center for Rheumatology, Albuquerque, New Mexico, United States
🇺🇸Omega Research Consultants, LLC, DeBary, Florida, United States
🇺🇸Stanford University, Palo Alto, California, United States
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 36
- Registration Number
- NCT02862535
Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults
- Conditions
- Interventions
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2020-02-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 48
- Registration Number
- NCT02858401
- Locations
- 🇺🇸
Midway Immunology & Research Center, Fort Pierce, Florida, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Mills Clinical Research, Los Angeles, California, United States
Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis
- Conditions
- Interventions
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 127
- Registration Number
- NCT02856555
Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)
- Conditions
- Interventions
- First Posted Date
- 2016-08-03
- Last Posted Date
- 2019-02-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 104
- Registration Number
- NCT02854631
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)
- Conditions
- Interventions
- First Posted Date
- 2016-08-03
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 140
- Registration Number
- NCT02854605
- Locations
- 🇨🇦
Toronto Liver Center, Toronto, Ontario, Canada
🇨🇦LMC Clinical Research Inc (Bayview), Toronto, Ontario, Canada
🇺🇸Clinical Research of South Florida, Coral Gables, Florida, United States
Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
- Conditions
- Interventions
- First Posted Date
- 2016-07-22
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 5399
- Registration Number
- NCT02842086
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)
- Conditions
- Interventions
- First Posted Date
- 2016-07-18
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 181
- Registration Number
- NCT02836249
- Locations
- 🇨🇳
Beijing Ditan Hospital, Beijing, China
🇨🇳PLA 302 Hospital, Beijing, China
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, China